key: cord-0748233-lcr1e8ch authors: Kawada, S.; Ogata, A.; Kato, Y.; Okamoto, M.; Yamaguchi, Y.; Morita, T.; Kumanogoh, A. title: The kinetic variations of anti-nucleocapsid antibody in SARS-CoV-2 infection date: 2021-02-08 journal: nan DOI: 10.1101/2021.02.05.21251208 sha: a41ff7e08ae2a935bb0557915db0f1a2401e871d doc_id: 748233 cord_uid: lcr1e8ch The humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a pivotal role in controlling coronavirus disease 2019 (COVID-19) infections. However, little is known about the persistence of the antibody response. We evaluated that the kinetics of anti-nucleocapsid protein antibody of SARS-CoV2 infected healthcare workers in COVID-19 cluster occurred hospital. The long-term kinetics of anti-N antibody was classified high and keep pattern, high and decay pattern, and low and keep pattern. COVID-19 contact and symptomaticity was not related to kinetic patterns. The reason of kinetic difference was still unclear. However natural anti-SARS-CoV-2 antibody persistence was not uniform, suggesting inter-individual difference of SARS-CoV2 vaccine efficacy. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2021. ; https://doi.org/10.1101/2021.02.05.21251208 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. AO; personal fees: Chugai, Eli Lilly, Asahi-Kasei Pharma, Daiichi Sankyo, Bristol-Myers Squibb, Janssen, Sanofi, GlaxoSmithKline, outside the submitted work. SK, YK, MO, YY, TM, and AK have nothing to disclose. SK and AO had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: AO and AK. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: SK, AO, and AK. Administrative, technical, or material support: SK, YK, MO, YY, TM. The study was approved by the local Ethics Committee of DOPH and registered in University Hospital Medical Information Network (UMIN) clinical trials registry in Japan (UMIN000040453). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 8, 2021. ; https://doi.org/10.1101/2021.02.05.21251208 doi: medRxiv preprint The data that support the findings of this study are available from the corresponding author upon reasonable request. Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research. The authors would like to thank Enago (www.enago.jp) for the English language review. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2021. ; https://doi.org/10.1101/2021.02.05.21251208 doi: medRxiv preprint The humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a pivotal role in controlling coronavirus disease 2019 (COVID-19) infections. However, little is known about the persistence of the antibody response. We evaluated that the kinetics of anti-nucleocapsid protein antibody of SARS-CoV2 infected healthcare workers in COVID-19 cluster occurred hospital. The long-term kinetics of anti-N antibody was classified high and keep pattern, high and decay pattern, and low and keep pattern. COVID-19 contact and symptomaticity was not related to kinetic patterns. The reason of kinetic difference was still unclear. However natural anti-SARS-CoV-2 antibody persistence was not uniform, suggesting inter-individual difference of SARS-CoV2 vaccine efficacy. The humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) plays a pivotal role in controlling coronavirus disease . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2021. ; https://doi.org/10.1101/2021.02.05.21251208 doi: medRxiv preprint method for evaluating immunity to SARS-CoV-2. However, little is known about the persistence of the antibody response. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2021. (Table 1) . Seropositivity persisted in all HCWs up to 7 months after diagnosis, and there were no reinfections of COVID-19. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2021. ; https://doi.org/10.1101/2021.02.05.21251208 doi: medRxiv preprint Most SARS-CoV-2 infected individuals display an antibody response within 21 days of infection. However, the persistence of antibodies against SARS-CoV-2 remains controversial. Some studies have reported robust antibody responses against SASR-CoV-2 (1,2), whereas others have reported declines in antibody titers (3, 4) . In our study, longitudinal change in anti-N antibodies was not uniform and was classified into three patterns: high levels of anti-N antibodies were obtained and maintained (high-keep); high levels of anti-N antibodies were obtained but declined (high-decay); and low levels of anti-N antibodies were obtained and maintained (low-keep). Antibody titers increased in some individuals. In our cohort, all HCWs were exposed to the COVID-19 outbreak at the hospital simultaneously. Additional close contact to COVID-19 was not reported in any HCWs. The antibody response was not boosted by re-exposure to SARS-CoV-2. The cause of kinetic variation of the anti-N antibody response was unclear but may be influenced by unknown interindividual differences in antibody response. Previous reports have demonstrated that severe infections exhibit a strong and prolonged antibody response (5) . Anti-S antibodies were enriched among recovering individuals, whereas anti-N antibodies were enriched in deceased individuals (6). In our study, disease severity was not correlated with the titer or kinetic pattern of anti-N . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 8, 2021. ; https://doi.org/10.1101/2021.02.05.21251208 doi: medRxiv preprint antibodies. Because the nucleocapsid protein of the COVID-19 virus is not exposed to the outside the virion, anti-N antibodies respond to destroyed or incomplete virus particles but not to infectable virus particles. Therefore, anti-N antibodies may not be related to disease recovery. The variation in antibody response raises questions concerning the efficacy of the SARS-CoV-2 vaccine. A personalized approach to boost the immune response to the SARS-CoV-2 vaccine may be necessary to eradicate COVID-19. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Humoral Immune Response to SARS-CoV-2 in Iceland Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19 Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 8, 2021. ; https://doi.org/10.1101/2021.02.05.21251208 doi: medRxiv preprint